Phototherapies for Psoriasis Market Set to Witness Significant Growth by 2025-2034

Introduction
Psoriasis is a chronic autoimmune skin condition characterized by rapid skin cell turnover, leading to scaling, inflammation, and plaques. Affecting millions globally, psoriasis is not only a dermatological concern but also a systemic disorder linked to comorbidities such as arthritis, cardiovascular disease, and metabolic syndrome.

Phototherapy has long been an established treatment option for moderate-to-severe psoriasis, leveraging controlled ultraviolet (UV) light to slow skin cell growth and reduce inflammation. Recent advancements in excimer lasers, narrowband UVB (NB-UVB), and home-use phototherapy devices are transforming the therapeutic landscape. Between 2024 and 2034, the phototherapies for psoriasis market is expected to expand steadily, driven by technological innovations, rising prevalence, and growing demand for non-invasive, drug-free treatment options.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71430

Market Overview
• 2024 Market Size: ~USD 1.9 billion
• 2034 Forecast: ~USD 3.3 billion
• CAGR (2025-2034): ~5.8%
• Key Growth Drivers: Rising psoriasis prevalence, demand for safer alternatives to systemic drugs, technological advancements in phototherapy devices, and increased patient awareness.
• Challenges: High equipment costs, risk of side effects with prolonged UV exposure, limited reimbursement policies, and competition from biologic therapies.
• Leading Players: Philips Healthcare, Daavlin, Lumenis, National Biological Corporation, Ultralite Enterprises, Alma Lasers, Merck KGaA, Johnson & Johnson, Pfizer, and AbbVie.

Phototherapy continues to be an essential therapy option, especially for patients not responding well to biologics or systemic drugs, highlighting its enduring role in psoriasis care.

Segmentation Analysis
By Technology
• Narrowband UVB (NB-UVB)
• Broadband UVB
• PUVA (Psoralen + UVA)
• Excimer Laser Therapy
• LED-Based Phototherapy
By Device Type
• Hospital-based full-body cabins
• Hand-held phototherapy devices
• Home-use portable devices

By End Use
• Hospitals
• Dermatology clinics
• Homecare settings

Summary:
NB-UVB remains the gold standard due to its balance of efficacy and safety. Excimer lasers are expanding for targeted therapy, while home-use devices are gaining popularity, improving accessibility for chronic patients.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71430/phototherapies-for-psoriasis-market

Regional Analysis
• North America: Largest market, supported by advanced healthcare systems, strong presence of device manufacturers, and high prevalence of psoriasis in the U.S.
• Europe: Significant adoption due to supportive healthcare policies and rising emphasis on non-drug therapies. Germany, France, and the UK lead demand.
• Asia-Pacific: Expected to record the fastest CAGR, fueled by growing psoriasis prevalence, increasing healthcare access, and rising demand for affordable phototherapy devices in China and India.
• Middle East & Africa: Gradual adoption, supported by expanding dermatology networks but limited by affordability challenges.
• Latin America: Brazil and Mexico lead regional demand, with rising dermatology access and public health awareness.

Regional Summary:
North America and Europe dominate revenues, but Asia-Pacific offers the strongest future growth potential due to its large patient pool and expanding healthcare infrastructure.

Market Dynamics
Key Growth Drivers
• Rising psoriasis prevalence worldwide, particularly moderate-to-severe cases.
• Increasing demand for non-pharmacological treatment options.
• Technological innovation in excimer laser and LED-based devices.
• Growth of home-based phototherapy for chronic management.
• Patient preference for long-term, drug-free therapies with fewer systemic side effects.

Key Challenges
• High upfront cost of phototherapy devices.
• Side effects including skin burns, premature aging, and increased risk of skin cancer with prolonged use.
• Competition from biologics and systemic drugs offering faster results.
• Limited insurance coverage and reimbursement in several regions.

Latest Trends
• Development of portable, AI-assisted phototherapy devices for home use.
• Integration of teledermatology platforms with home phototherapy.
• Increasing use of excimer laser therapy for localized, resistant plaques.
• Growing interest in LED-based phototherapy systems for safety and cost-effectiveness.
• Expansion of clinical studies combining phototherapy with biologics for synergistic effects.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71430

Competitor Analysis
Major Players
• Philips Healthcare - Market leader in phototherapy devices with a strong global presence.
• Daavlin - Specialized in NB-UVB and home-use phototherapy systems.
• Lumenis & Alma Lasers - Leaders in excimer and energy-based dermatology devices.
• National Biological Corporation & Ultralite Enterprises - Focused on hospital and clinic phototherapy systems.
• Merck KGaA - Active in psoriasis management with complementary drug therapies.
• Johnson & Johnson, Pfizer, AbbVie - Indirect competition through biologic psoriasis therapies.

Summary:
The market is split between device manufacturers driving phototherapy adoption and pharmaceutical companies competing with biologic and systemic drug alternatives. Innovation in device design and integration with digital health platforms is a key competitive advantage.

Conclusion
The global phototherapies for psoriasis market is projected to grow from USD 1.9 billion in 2024 to nearly USD 3.3 billion by 2034, at a CAGR of 5.8%. Phototherapy remains a vital treatment option, particularly for patients who prefer drug-free management or have contraindications to systemic therapies.

Key Takeaways:
• NB-UVB is the gold standard, but excimer laser and LED-based therapies are expanding.
• North America and Europe lead revenues, while Asia-Pacific is the fastest-growing region.
• Rising patient preference for home-use devices is reshaping treatment accessibility.
• Challenges include high equipment costs, reimbursement gaps, and long-term safety concerns.
• The future will see AI-enabled devices, teledermatology integration, and combination therapies strengthening phototherapy's role in psoriasis care.

This report is also available in the following languages : Japanese (乾癬に対する光線療法市場), Korean (건선 시장을 위한 광선 요법), Chinese (银屑病光疗法市场), French (Marché des photothérapies pour le psoriasis), German (Phototherapien für den Psoriasis-Markt), and Italian (Mercato delle fototerapie per la psoriasi), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71430

Our More Reports:

Adeno-Associated Virus Vectors in Gene Therapy Market
https://exactitudeconsultancy.com/reports/71642/adeno-associated-virus-vectors-in-gene-therapy-market

22q11.2 Deletion Syndrome Market
https://exactitudeconsultancy.com/reports/71644/22q11-2-deletion-syndrome-market

Alpha-1 Antitrypsin Deficiency Market
https://exactitudeconsultancy.com/reports/71646/alpha-1-antitrypsin-deficiency-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.